Bladder Cancer Clinical Trials in Los Angeles, California
19 recruitingLos Angeles, California
Showing 1–19 of 19 trials
Recruiting
Phase 2
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Stage IV Renal Cell Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8Large Cell Neuroendocrine Carcinoma+42 more
National Cancer Institute (NCI)314 enrolled579 locationsNCT03866382
Recruiting
Phase 2
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
Muscle Invasive Bladder Urothelial CarcinomaStage II Bladder Cancer AJCC v8Stage IIIA Bladder Cancer AJCC v8
National Cancer Institute (NCI)111 enrolled134 locationsNCT07061964
Recruiting
Phase 1Phase 2
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
Non-muscle Invasive Bladder Cancer With Carcinoma in SituSuperficial Bladder Cancer
enGene, Inc.350 enrolled101 locationsNCT04752722
Recruiting
Phase 3
Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer
Intermediate Risk Non-Muscle Invasive Bladder Cancer
Ferring Pharmaceuticals454 enrolled82 locationsNCT06510374
Recruiting
Phase 2
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
Stage I Bladder Cancer AJCC v8Non-Muscle Invasive Bladder Urothelial CarcinomaRecurrent Non-Muscle Invasive Bladder Urothelial Carcinoma
National Cancer Institute (NCI)160 enrolled124 locationsNCT06770582
Recruiting
Phase 3
A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer
Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
Ferring Pharmaceuticals250 enrolled66 locationsNCT06545955
Recruiting
Phase 1
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
Esophageal Squamous Cell CarcinomaCutaneous Squamous Cell CancerBladder Cancer+8 more
EvolveImmune United, Inc160 enrolled9 locationsNCT07217171
Recruiting
Phase 2
Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes
Advanced Bladder CarcinomaMetastatic Bladder CarcinomaStage IV Bladder Cancer AJCC v8+3 more
National Cancer Institute (NCI)60 enrolled17 locationsNCT03375307
Recruiting
Phase 1
A Phase 1/1b Study of IAM1363 in HER2 Cancers
HER2-positive Breast CancerHER2 + Breast CancerHER2 Mutation-Related Tumors+10 more
Iambic Therapeutics, Inc383 enrolled48 locationsNCT06253871
Recruiting
Phase 1
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Urothelial CarcinomaBladder CancerAdvanced/Metastatic Solid Tumors+1 more
Pfizer310 enrolled28 locationsNCT07090499
Recruiting
Not Applicable
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
Liver CancerBiliary Tract CancerColon Cancer+76 more
Cedars-Sinai Medical Center360 enrolled1 locationNCT04907643
Recruiting
Phase 1
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Breast CancerOvarian CancerProstate Cancer+8 more
Clasp Therapeutics, Inc.90 enrolled21 locationsNCT06778863
Recruiting
A Novel Multiplex ELISA Assay for Surveilling Patients With History of Bladder Cancer
Bladder Cancer
Cedars-Sinai Medical Center300 enrolled4 locationsNCT03193515
Recruiting
Predicting BCG Response
Bladder Cancer
Cedars-Sinai Medical Center400 enrolled5 locationsNCT04564781
Recruiting
A Novel Multiplex ELISA Assay for Evaluating Patients With Microscopic Hematuria for Bladder Cancer
Bladder Cancer
Cedars-Sinai Medical Center900 enrolled8 locationsNCT03193541
Recruiting
Blue Light Cystoscopy With Cysview® Registry
Bladder Cancer
Photocure4,400 enrolled23 locationsNCT02660645
Recruiting
Phase 1Phase 2
A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer
Non Muscle Invasive Bladder Cancer
ImmunityBio, Inc.596 enrolled80 locationsNCT02138734
Recruiting
Not Applicable
Bladder Fiducial Markers and Multiparametric-MRI (Mp-MRI) to Optimize Bladder Chemo-radiotherapy
Bladder CancerNeoplasmsUrinary Bladder Neoplasm+2 more
Cedars-Sinai Medical Center60 enrolled3 locationsNCT04442724
Recruiting
Not Applicable
Deceased Donor Bladder or Combined Kidney-bladder Transplantation: a Phase 0 First-in-human Study
Bladder CancerKidney FailureBladder Disease+1 more
University of California, Los Angeles5 enrolled1 locationNCT06337942